Details of the Drug Combinations

General Information of This Drug (ID: DMGDKXN)

• Drug Name: Sitagliptin (DMGDKXN)
• Synonyms: 486460-32-6; Januvia; Xelevia; Sitagliptan; MK-0431; UNII-QFP0P1DV7Z; Tesavel; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; CHEBI:40237; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; Janumet; Sitagliptin phosphate; Januvia (TN); Sitagliptin (PropINN); Januvia (merck & Co); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin/atovastatin

Indication

Cystic fibrosis; ICD 11: CA25; Status: Approved [1]; Non-insulin dependent diabetes; ICD 11: 5A11; Status: Approved [1]; Renal hypoplasia; ICD 11: N.A.; Status: Approved [1]; Type-2 diabetes; ICD 11: 5A11; Status: Approved [2]; Peripheral arterial disease; ICD 11: BD4Z; Status: Phase 1/2 [3]

• Therapeutic Class: Hypoglycemic Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

50 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Acamprosate + Sitagliptin	DCAVSLI	Acamprosate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Atovaquone + Sitagliptin	DCVV2S2	Atovaquone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Benserazide + Sitagliptin	DCZVGWU	Benserazide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Dantrolene + Sitagliptin	DC5UONS	Dantrolene	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Diazoxide + Sitagliptin	DCZM3CB	Diazoxide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Diethylcarbamazine + Sitagliptin	DC360O1	Diethylcarbamazine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Docetaxel + Sitagliptin	DCRB7KG	Docetaxel	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Doxorubicin + Sitagliptin	DCKRU0G	Doxorubicin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
ETHISTERONE + Sitagliptin	DC7NXO1	ETHISTERONE	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Kanamycin + Sitagliptin	DCA1E3E	Kanamycin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Leflunomide + Sitagliptin	DCXIE6S	Leflunomide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Levamisole + Sitagliptin	DC2OWC7	Levamisole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Lumefantrine + Sitagliptin	DCU0U7Y	Lumefantrine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Methotrexate + Sitagliptin	DCGRQDU	Methotrexate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Moricizine + Sitagliptin	DCDXJDI	Moricizine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Phensuximide + Sitagliptin	DC0V1YC	Phensuximide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Quinine + Sitagliptin	DC4A9NU	Quinine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Ribavirin-TP + Sitagliptin	DCF1ZR5	Ribavirin-TP	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Mebutamate	DCVW1N1	Mebutamate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Bepridil	DCDOG1G	Bepridil	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Diethylcarbamazine	DCKCY2V	Diethylcarbamazine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Miglustat	DCTQWJQ	Miglustat	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Vinblastine	DCZEXHJ	Vinblastine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Fomepizole	DC6RCR9	Fomepizole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Everolimus	DCYXX0J	Everolimus	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + 10-hydroxycamptothecin	DCCL7JT	10-hydroxycamptothecin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Pamidronate	DCUSBEL	Pamidronate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Palonosetron	DCZG0DO	Palonosetron	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Metyrosine	DCTF6ED	Metyrosine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Chlorzoxazone	DCH06NA	Chlorzoxazone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Galantamine	DCT6KUP	Galantamine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + JZL195	DCF25WJ	JZL195	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Fibrates	DCHJ5YQ	Fibrates	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + WAY-100635	DC54H71	WAY-100635	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + BIO-300	DCPYCLD	BIO-300	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Idarubicin	DCBKMB1	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]
Sitagliptin + Linagliptin	DCEA6RP	Linagliptin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Methylene blue	DCHPW6T	Methylene blue	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Trimethobenzamide	DCAC4DR	Trimethobenzamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Maprotiline	DC56OQJ	Maprotiline	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Acetohexamide	DCNR676	Acetohexamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Brincidofovir	DCNJC0W	Brincidofovir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Desoxycorticosterone pivalate	DCRPA7A	Desoxycorticosterone pivalate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Hyodeoxycholic acid	DC1T5HZ	Hyodeoxycholic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Mycophenolic acid	DC42QZZ	Mycophenolic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Mefloquine	DCONIPB	Mefloquine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + PMID28870136-Compound-43	DCPM904	PMID28870136-Compound-43	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Estramustine	DCTC3I4	Estramustine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Sitagliptin + Cerivastatin	DCDL5JU	Cerivastatin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Testolactone + Sitagliptin	DCT3ZFE	Testolactone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]

1 Discontinued Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Atorvastatin + Sitagliptin	DCJVFYJ	Atorvastatin	Cardiovascular disease	[5]

17 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Alogliptin + Sitagliptin	DC1333J	Alogliptin	Type 2 Diabetes Mellitus	[6]
Canagliflozin + Sitagliptin	DC96HDS	Canagliflozin	Type2 Diabetes Mellitus	[7]
Dapagliflozin + Sitagliptin	DCCDZZE	Dapagliflozin	Type 2 Diabetes Mellitus	[8]
Liraglutide + Sitagliptin	DCQ63IQ	Liraglutide	Diabetes	[9]
Metformin + Sitagliptin	DCDEZAK	Metformin	Type 2 Diabetes	[10]
Metformin + Sitagliptin	DCRRXIM	Metformin	Type 2 Diabetes Mellitus	[11]
Metformin + Sitagliptin	DCRTDAX	Metformin	Type-2 diabetes	[12]
Sitagliptin + Enalapril	DC6T1FG	Enalapril	Metabolic Syndrome	[13]
Sitagliptin + Exenatide	DCKPDVR	Exenatide	Type 2 Diabetes Mellitus	[14]
Sitagliptin + Pantoprazole	DCLFHVF	Pantoprazole	Type 1 Diabetes	[15]
Sitagliptin + Voglibose	DCTADP5	Voglibose	Diabetes Mellitus, Non-Insulin-Dependent	[16]
Sitagliptin + Danazol	DC64TIH	Danazol	Immune Thrombocytopenia	[17]
Glimepiride + Sitagliptin	DC9T0X0	Glimepiride	Type 2 Diabetes Mellitus	[18]
Sitagliptin + ASP1941	DCCZETX	ASP1941	Type 2 Diabetes Mellitus	[19]
Insulin-lispro + Sitagliptin	DCPQ5DJ	Insulin-lispro	Type 2 Diabetes	[20]
Metformin + Sitagliptin	DC3BI0L	Metformin	Type 2 Diabetes Mellitus	[21]
Sitagliptin + Insulin-glargine	DCY47RE	Insulin-glargine	Type 2 Diabetes	[22]

References

• [1] Sitagliptin FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6286).
• [3] ClinicalTrials.gov (NCT01619332) Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763. U.S. National Institutes of Health.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] Clinical pipeline report, company report or official report of Merck.
• [6] ClinicalTrials.gov (NCT01588587) DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients
• [7] ClinicalTrials.gov (NCT02956044) Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
• [8] ClinicalTrials.gov (NCT00842556) Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
• [9] ClinicalTrials.gov (NCT02077946) A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden
• [10] ClinicalTrials.gov (NCT00961480) A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)
• [11] ClinicalTrials.gov (NCT00420511) Beta-Cell Function and Sitagliptin Trial (BEST)
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] ClinicalTrials.gov (NCT00666848) Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome
• [14] ClinicalTrials.gov (NCT00477581) A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus
• [15] ClinicalTrials.gov (NCT00768651) Incretin Effect and Use After Clinical Islet Transplantation
• [16] ClinicalTrials.gov (NCT00837577) MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
• [17] ClinicalTrials.gov (NCT05353673) The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
• [18] ClinicalTrials.gov (NCT01177384) Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
• [19] ClinicalTrials.gov (NCT02564211) Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
• [20] ClinicalTrials.gov (NCT05579119) SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)
• [21] ClinicalTrials.gov (NCT01709305) A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
• [22] ClinicalTrials.gov (NCT01845831) Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes